NA-Selank Amidate
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
NA-Selank Amidate is a modified analog of Selank, a synthetic heptapeptide originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a derivative of the endogenous immune peptide tuftsin. The “NA” and “amidate” refer to chemical modifications — an acetyl group added to one end of the peptide and an amide group to the other — that are reported to increase the molecule’s stability and its ability to cross the blood-brain barrier.
Selank and its analogs are discussed primarily as anxiolytic nootropics: compounds studied for reducing anxiety while supporting mood and cognition. The parent peptide has an unusually large body of clinical work for a research peptide, including human studies in generalized anxiety disorder and neurasthenia conducted in Russia.
The amidated analog itself has little independent peer-reviewed literature. Most of the evidence below comes from studies on unmodified Selank, and how closely the analog reproduces those effects in humans is not established.
How it works
In preclinical and early clinical research, Selank is reported to act on several neurotransmitter systems at once rather than a single receptor. It is described as modulating GABAergic signaling — though, unlike benzodiazepines, it does not appear to bind the classic benzodiazepine site — and as helping normalize serotonin and dopamine turnover. It has also been studied for inhibiting the breakdown of enkephalins, which may preserve endogenous opioid tone.
A frequently cited mechanism is the upregulation of brain-derived neurotrophic factor (BDNF). In rodent studies, intranasal Selank increased BDNF expression in the hippocampus, a change thought to support synaptic plasticity and to underlie the reported anxiolytic and cognitive effects. The precise mechanism in humans, and how the amidated analog compares, remains uncertain.
Reported benefits
- Reduced anxiety without the sedation typically seen with benzodiazepines (clinical and animal data on Selank)
- Support for focus, mental clarity, and memory
- More stable mood and resilience to stress
- Possible immune-modulating effects, reflecting its tuftsin origin
These are reported and studied effects, not guaranteed outcomes, and much of the supporting data comes from the parent peptide rather than the amidated analog.
Considerations & side effects
Because independent human data on the amidated analog is scarce, its safety profile is not well characterized, and long-term effects are unknown. Reported side effects for Selank are generally mild and can include a temporary altered sense of taste or smell with intranasal use, mild fatigue or drowsiness, and irritation at the site of administration.
Purity varies widely in the research-chemical market, and products sold under this name are not manufactured to pharmaceutical standards. This information is educational and is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is NA-Selank Amidate?
A modified synthetic analog of Selank, a heptapeptide derived from the immune-signaling molecule tuftsin. It is acetylated at one end and amidated at the other, changes intended to improve stability and blood-brain barrier penetration. It is studied as an anxiolytic (anti-anxiety) nootropic.
How is it different from regular Selank?
The N-terminal acetyl group and C-terminal amide are structural modifications reported to make the molecule more lipophilic and more resistant to enzymatic breakdown, which may extend its duration of action. Most published research is on unmodified Selank rather than this analog specifically.
Is NA-Selank Amidate FDA-approved?
No. It is not approved by the FDA or any major Western regulator for human use and is sold for research purposes only. The parent peptide Selank is approved as a medicine in Russia but not elsewhere.
Is it a stimulant or a sedative?
Neither in the conventional sense. Selank is commonly described as anxiolytic without the sedation, tolerance, or dependence associated with benzodiazepines, though this characterization rests largely on preclinical and limited clinical data.
References
- Zozulia AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in generalized anxiety disorders and neurasthenia. ↗
- Inozemtseva LS, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. ↗
- Filatova E, et al. GABA, Selank, and Olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. ↗
Related compounds
Synthetic analog of the immune peptide tuftsin with anxiolytic and nootropic properties. Modulates GABA and serotonin systems without sedation or dependence.
Four-peptide cognitive enhancement blend combining NA-Selank, NA-Semax, PE-22-28, and Pinealon. Targets neuroprotection, cognitive enhancement, and mood support. Sold as a single pre-mixed vial.
Synthetic heptapeptide derived from Spadin. Acts as a TREK-1 potassium channel blocker with rapid antidepressant effects and enhanced neurogenesis. 300-500x more potent than full-length Spadin.